Search results
Results from the WOW.Com Content Network
Corticobasal degeneration (CBD) is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. [1] CBD symptoms typically begin in people from 50 to 70 years of age, and typical survival before death is eight years.
Corticobasal syndrome (CBS) is a rare, progressive atypical Parkinsonism syndrome and is a tauopathy related to frontotemporal dementia. [ 1 ] [ 2 ] CBS is typically caused by the deposit of tau proteins forming in different areas of the brain.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
The five-year survival rate is a type of survival rate for estimating the prognosis of a particular disease, normally calculated from the point of diagnosis. [1] Lead time bias from earlier diagnosis can affect interpretation of the five-year survival rate.
Duke treadmill scores typically range from -25 (highest risk) to +15 (lowest risk). One-year mortality and five-year survival rates respectively for the results of the Duke treadmill score have been reported as: [4] [5] [6] less or equal to -11: 5.25% / 65% 4 to -10: 1.25% / 90% more or equal to 5: 0.25% / 97%
Human infectious diseases may be characterized by their case fatality rate (CFR), the proportion of people diagnosed with a disease who die from it (cf. mortality rate).It should not be confused with the infection fatality rate (IFR), the estimated proportion of people infected by a disease-causing agent, including asymptomatic and undiagnosed infections, who die from the disease.
The Baux score is a system used to predict the chance of mortality due to burns. [1] The score is an index which takes into account the correlative and causal relationship between mortality and factors including advancing age, burn size, the presence of inhalational injury. [2]
The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference. In 1993, a retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a doxorubicin -based chemotherapy regimen such as CHOP between 1982 and 1987. [ 2 ]